CL2015002627A1 - Compositions for use in the treatment of eye disorders using dipyridamole - Google Patents

Compositions for use in the treatment of eye disorders using dipyridamole

Info

Publication number
CL2015002627A1
CL2015002627A1 CL2015002627A CL2015002627A CL2015002627A1 CL 2015002627 A1 CL2015002627 A1 CL 2015002627A1 CL 2015002627 A CL2015002627 A CL 2015002627A CL 2015002627 A CL2015002627 A CL 2015002627A CL 2015002627 A1 CL2015002627 A1 CL 2015002627A1
Authority
CL
Chile
Prior art keywords
treatment
compositions
dipiridamol
preferibly
eye disorders
Prior art date
Application number
CL2015002627A
Other languages
Spanish (es)
Inventor
Moshe Rogosnitzky
Original Assignee
Remedeye Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remedeye Inc filed Critical Remedeye Inc
Publication of CL2015002627A1 publication Critical patent/CL2015002627A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCIÓN DESCRIBE COMPOSICIONES PARA EL USO EN EL TRATAMIENTO DE TRASTORNOS OCULARES, LAS COMPOSICIONES QUE INCLUYEN UNA CANTIDAD EFECTIVA DE UN DIPIRIDAMOL ADMINISTRADO TÓPICAMENTE. PREFERIBLEMENTE, EL DIPIRIDAMOL ADMINISTRADO TÓPICAMENTE ES FORMULADO COMO UNA SOIUCION. PREFERIBLEMENTE, EL DIPIRIDAMOL ADMINISTRADO TÓPICAMENTE ES AL MENOS UN AGENTE SELECCIONADO DEL GRUPO QUE CONSISTENTE DE: DIPIRIDAMOL, Y SU SAL FARMACÉUTICAMENTE ACEPTABLE. PREFERIBLEMENTE, LA CANTIDAD EFECTIVA CORRESPONDE A UNA CONCENTRACIÓN DE POR LO MENOS APROXIMADARNENTE UNA MOLARIDAD DE 10-5. PREFERIBLEMENTE, LA CANTIDAD EFECTIVA SE BASA EN LA ADMINISTRACIÓN DE UN TRATAMIENTO DE AL MENOS UNA VEZ CADA DOS DIAS.THIS INVENTION DESCRIBES COMPOSITIONS FOR USE IN THE TREATMENT OF EYE DISORDERS, COMPOSITIONS THAT INCLUDE AN EFFECTIVE AMOUNT OF A TYPICALLY ADMINISTERED DIPIRIDAMOL. PREFERIBLY, DIPIRIDAMOL ADMINISTERED TYPICALLY IS FORMULATED AS A SOIUTION. PREFERIBLY, THE TYPICALLY ADMINISTERED DIPIRIDAMOL IS AT LEAST AN AGENT SELECTED FROM THE GROUP THAT CONSISTS OF: DIPIRIDAMOL, AND ITS PHARMACEUTICALLY ACCEPTABLE SALT. PREFERIBLY, THE EFFECTIVE AMOUNT CORRESPONDS TO A CONCENTRATION OF AT LEAST APPROXIMATELY A 10-5 MOLARITY. PREFERIBLY, THE EFFECTIVE AMOUNT IS BASED ON THE ADMINISTRATION OF A TREATMENT OF AT LEAST ONCE EVERY TWO DAYS.

CL2015002627A 2013-03-12 2015-09-11 Compositions for use in the treatment of eye disorders using dipyridamole CL2015002627A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL225179A IL225179A (en) 2013-03-12 2013-03-12 Compositions for use in treating eye disorders using dipyridamole

Publications (1)

Publication Number Publication Date
CL2015002627A1 true CL2015002627A1 (en) 2016-03-11

Family

ID=48916407

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002627A CL2015002627A1 (en) 2013-03-12 2015-09-11 Compositions for use in the treatment of eye disorders using dipyridamole

Country Status (14)

Country Link
EP (1) EP2968328A4 (en)
JP (1) JP6820658B2 (en)
KR (2) KR20150126021A (en)
CN (1) CN105188702B (en)
AU (1) AU2014229371B2 (en)
BR (1) BR112015022084A2 (en)
CA (1) CA2905594A1 (en)
CL (1) CL2015002627A1 (en)
EA (1) EA035966B1 (en)
IL (1) IL225179A (en)
MX (1) MX2015012716A (en)
MY (1) MY182591A (en)
SG (2) SG10201706937UA (en)
WO (1) WO2014141079A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107106541A (en) * 2015-01-28 2017-08-29 瑞采生技有限公司 Compound and its medical application for strengthening PPAR γ performances and nuclear translocation
US20180092776A1 (en) 2016-09-30 2018-04-05 Sara Heikali Method and device for treating and managing diseased ocular tissue
WO2021001805A1 (en) 2019-07-04 2021-01-07 Ocular Discovery Ltd. Stable dipyridamole formulations and their methods of preparation
WO2021001806A1 (en) 2019-07-04 2021-01-07 Ocular Discovery Ltd. Stable dipyridamole formulations with reduced impurities
WO2024125322A1 (en) * 2022-12-16 2024-06-20 智泽童康(广州)生物科技有限公司 Dipyridamole for preventing and treating allergic and/or inflammatory diseases and preparation thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07258084A (en) * 1994-03-17 1995-10-09 Rohto Pharmaceut Co Ltd Intracular pressure-reducing agent containing dipyridamole as essential component
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
AU2006311577B2 (en) * 2005-11-09 2013-02-07 Zalicus Inc. Methods, compositions, and kits for the treatment of medical conditions
WO2010056710A1 (en) * 2008-11-11 2010-05-20 Biovista, Inc. Compositions and methods for treating eye diseases
EP2363126A1 (en) * 2010-03-04 2011-09-07 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Composition comprising as active ingredient L-carnitine in combination with hydroxykynurenine-O-beta-DL-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation

Also Published As

Publication number Publication date
SG11201507092QA (en) 2015-10-29
IL225179A (en) 2017-01-31
JP2016514123A (en) 2016-05-19
MX2015012716A (en) 2016-07-06
SG10201706937UA (en) 2017-09-28
CA2905594A1 (en) 2014-09-18
BR112015022084A2 (en) 2017-07-18
EA201591653A1 (en) 2017-05-31
MY182591A (en) 2021-01-26
JP6820658B2 (en) 2021-01-27
EP2968328A4 (en) 2016-11-23
KR20210010638A (en) 2021-01-27
CN105188702A (en) 2015-12-23
KR20150126021A (en) 2015-11-10
CN105188702B (en) 2019-03-26
IL225179A0 (en) 2013-06-27
EA035966B1 (en) 2020-09-07
AU2014229371B2 (en) 2018-05-10
WO2014141079A1 (en) 2014-09-18
AU2014229371A1 (en) 2015-10-29
EP2968328A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
BR112015027282A8 (en) liquid formulation and kit comprising fenfluramine, and uses thereof in the treatment of dravet syndrome
EA201790195A1 (en) METHODS OF TREATING CANCER WITH THE USE OF TIGIT INHIBITORS AND ANTI-CANCER AGENTS
EA201890725A1 (en) PHARNESIDE X-RECEPTOR AGONISTS AND THEIR APPLICATION
BR112015029491A2 (en) imidazopyrrolidinone derivatives and their use in the treatment of disease
BR112018015273A2 (en) benzimidazole derivatives as ror-gamma modulators
BR112015020389A2 (en) carbazole compounds useful as bromodomain inhibitors
BR112015029512A8 (en) pyrazolopyrrolidine derivatives, their uses, and pharmaceutical composition and combination
EA201690044A1 (en) NUCLEAR TRANSPORT MODULATORS AND THEIR APPLICATION
CO2018008421A2 (en) Indoline derivatives substituted as inhibitors of dengue viral replication
CL2015002627A1 (en) Compositions for use in the treatment of eye disorders using dipyridamole
CO2018009563A2 (en) Indoline derivatives substituted as inhibitors of dengue viral replication
CO6821938A2 (en) A guanidine compound or salt thereof for the treatment of diseases related to vap -1
BR112016007946A2 (en) pharmaceutical combination, uses thereof, plinabulin and composition, kits or mixtures and methods for treating and / or preventing cancer
BR112015029401A8 (en) pyrazolo-pyrrolidin-4-one derivatives, their uses, and pharmaceutical composition and combination
EA201692481A1 (en) COMBINATION CONTAINING GLUCOCORTICOID AND EDO-S101
BR112018005905A2 (en) ? compound, pharmaceutical composition, methods to prevent or treat a disease or condition, organ damage, hepatotoxicity and fatty liver, and, use of a compound?
AR096892A1 (en) A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA
BR112016026545A8 (en) eribulin or a pharmaceutically acceptable salt thereof, its uses and kit for use in the treatment of breast cancer
EA201690323A1 (en) METHODS OF TREATING EAR DISEASES IN CHILDREN
EA201692111A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DANIRYXIN FOR TREATING INFECTIOUS DISEASES
BR112017021583A2 (en) Methods for treating inflammatory disorders
DOP2016000003A (en) STABILIZED PHARMACEUTICAL DOSAGE FORMS THAT INCLUDE BACK
CL2019003463A1 (en) Pharmaceutical composition and pharmaceutical dosage form comprising (e) -4- (2- (aminomethyl) -3-fluoroallyloxy) -n-tert-butylbenzamide, process for its preparation, methods for treatment and uses thereof.
PE20151300A1 (en) TOPICAL ANTIFUNGAL COMPOSITION FOR THE TREATMENT OF ONICHOMYCOSIS
BR112014015578A8 (en) topical pharmaceutical compositions comprising bexarotene and a corticosteroid